| Document |
Document Title |
|
WO/2020/244686A1 |
The present invention relates to compounds of general formula (I), wherein - X is selected from a group consisting of H; C1 to C6, alkyl; halogen (F, Cl, Br or I); Y is selected from a group consisting of nitrogen; N-oxide; Z1, Z2, Zm, w...
|
|
WO/2020/242948A1 |
The application is drawn to 18F-radiolabeled residualizing agents and biomolecules and methods for radiolabeling biomolecules with radioactive fluorine atoms. The biomolecules have an affinity for particular types of cells and may specif...
|
|
WO/2020/243638A1 |
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
|
|
WO/2020/243650A1 |
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
|
|
WO/2020/225386A1 |
The invention relates to a compound of general formula (E)-I or (Z)-I, where Y is a hydroxy group or an O-M+- group, wherein M+ is a cation; Z1 is selected from the group that consists of a substituted or unsubstituted C1-C12 alkyl group...
|
|
WO/2020/221744A1 |
The present invention relates to a method for radioiodination or radioastatination of a biomolecule such as proteins and antibodies by reacting a biomolecule carrying a hetero(aryl) boronic acid group with a radioiodide or astatide salt,...
|
|
WO/2020/222041A1 |
This invention provides a novel method that is simple, efficient, and allows for a reliable production of fluorine- 18 (18F) radiofluorinated compounds and radiopharmaceuticals. The method comprises an "in-loop" process, where an 18F sou...
|
|
WO/2020/215791A1 |
The present document discloses an isotope-labeled bionic sugar or sugar group, a preparation method and an application thereof Specifically, the isotope-labeled bionic sugar or sugar group disclosed in the present document comprises a re...
|
|
WO/2020/210914A1 |
The invention relates to compounds for use in imaging and/or for the diagnosis of conditions or diseases associated with an altered level of Neprilysin (NEP/CD10) in a subject having, or suspected of having said conditions or diseases. I...
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/178795A1 |
The present disclosure relates to [18F]-labeled benzothiazole derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in ...
|
|
WO/2020/163653A1 |
Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.
|
|
WO/2020/157184A1 |
The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety ...
|
|
WO/2020/159904A1 |
Compounds having the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
|
|
WO/2020/157128A1 |
A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labeled ...
|
|
WO/2020/157177A1 |
The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.
|
|
WO/2020/148154A1 |
The invention concerns a compound according to following formula, wherein R1 is an F or an I residue.
|
|
WO/2020/131918A1 |
The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-p
regnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharm...
|
|
WO/2020/119206A1 |
Disclosed are a radioactive iodine-labelled Larotrectinib compound, a preparation method therefor and the use thereof. The radioactive iodine-labelled Larotrectinib compound includes a radioactive iodine-labelled Larotrectinib compound o...
|
|
WO/2020/115715A1 |
The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined as set forth in the ...
|
|
WO/2020/108688A1 |
The Invention relates to a compound of general formula (I), where Ar is a pyridine ring. Also provided is a precursor compound for preparing a compound of formula (I), which has a nucleofuge in place of a group R1.
|
|
WO/2020/103392A1 |
Disclosed in the present invention are an 18F-PET/CT tracer comprising 7-deazaadenine base as a parent nucleus and a preparation method therefor. Disclosed in the present invention are a compound represented by formula I or a pharmaceuti...
|
|
WO/2020/102596A1 |
Deuterated polyunsaturated fatty acid ("PUFA") compounds, compositions, and uses of the compounds for reducing lipid autooxidation and the treatment of various diseases and conditions are provided.
|
|
WO/2020/099398A1 |
A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their u...
|
|
WO/2020/102737A1 |
Disclosed herein are compounds and methods for labeling and quantifying analytes using mass spectrometry.
|
|
WO/2020/099770A1 |
The invention relates to a method for transferring a radioisotope that is attached to a first stationary phase contained in a first chromatography column to a second stationary phase contained in a second chromatography column, in order ...
|
|
WO/2020/089379A1 |
The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the sy...
|
|
WO/2020/088767A1 |
The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the sy...
|
|
WO/2020/084267A1 |
The present invention concerns compounds of the following general structure (I): (I) in which A, B, C, D, L1, L2, L3, L4, n and m are as defined in claim 1. The invention also concerns the use of these compounds for an application for ne...
|
|
WO/2020/065047A1 |
The present invention provides a novel method for the controlled stereoisomerization (comprising the stereo-conversion of chiral compounds to racemates, non-racemic mixtures and mixtures of epimers). The method of the invention provides ...
|
|
WO/2020/059986A1 |
The present invention relates to a method for preparing a fluorine-18-labeled fluoromethyl-substituted radiopharmaceutical using selective azide substitution reaction, the method comprising: a first step for obtaining [18F]fluoride from ...
|
|
WO/2020/061458A1 |
The disclosure pertains to drug delivery conjugates for targeted therapy. The disclosure relates to methods of treating PSMA expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac. The disclos...
|
|
WO/2020/053596A1 |
The invention relates to a process for producing a compound comprising the anion [CF2 18FSO2]-, which process comprises treating a difluorocarbene source with (i) a source of 18F- and (ii) a source of SO2. The invention relates to a comp...
|
|
WO/2020/035782A1 |
The present invention relates to compounds according to structure (I) whereby one of R1 to R3 is -OCOCD3 and the other two are either hydroxyl or OAc, their synthesis and their use in for the analysis of the metabolism of glycolysis inhi...
|
|
WO/2020/035518A1 |
In a method (100 to 208) in which hyperpolarizable tracer molecules (20, 88 to 98) are hydrogenated and then optionally also hyperpolarized for magnetic resonance imaging, it is proposed that, in a first method step (104, 202), a hydroge...
|
|
WO/2020/032038A1 |
The present invention provides a compound represented by formula (I), which has high specificity and high selectivity for monoamine oxidase B, and which is capable of imaging monoamine oxidase B with a good sensitivity, or a pharmaceutic...
|
|
WO/2020/017557A1 |
Provided are: a compound suitable for imaging an intracerebral TRPV1 receptor; and a use thereof. A compound or a salt thereof represented by formula (I) is used. [In formula (1), R1 is a hydrogen or a random organic group; R2 is an orga...
|
|
WO/2020/010228A1 |
Disclosed herein, inter alia, are deconstructive functionalization methods and compounds made using the same.
|
|
WO/2020/007893A1 |
The present invention refers to reagents and methods for preparing a peptide sequence having a [18F]fluoro-aromatic amino acid side which may be further substituted, in particular a 4-[18F]fluoro-phenylalanine side chain in peptide seque...
|
|
WO/2020/002314A1 |
The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
|
|
WO/2020/002634A1 |
The present invention relates to specific nitrogen containing compounds of formulas (I), (II) and (IV) of the present invention, which are suitable to be used in a method to detect alkyne group containing organic compounds by mass spectr...
|
|
WO/2019/236483A1 |
The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular pro...
|
|
WO/2019/210422A1 |
The present disclosure relates to Vitamin E derivatives as multi-scale imaging agents. In particular, the present disclosure relates to isotopically labeled Vitamin E derivatives, and their use as multi-scale imaging agents.
|
|
WO/2019/204335A1 |
The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a compound of the formula 1. The invention described her...
|
|
WO/2019/200131A1 |
The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the cera...
|
|
WO/2019/193068A1 |
The present invention relates to a process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group. The present invention also concerns the use of carbon labeled organic compounds containing a ca...
|
|
WO/2019/192912A1 |
There is provided a synthesis of [18F]SFB (N-succinimidyl 4-[18F]fluorobenzoate) using a one-step reaction procedure without generating radioactive waste gases. [18F]SFB is useful as a reagent for labeling of low- and high-molecular weig...
|
|
WO/2019/191642A1 |
Provided herein are methods and labeling kits for synthesizing 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyl-u
racil in a one-pot reaction in compliance with CGMP. Also disclosed are labeling kits that can be assembled in an...
|
|
WO/2019/185932A1 |
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises...
|
|
WO/2019/185933A1 |
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method...
|
